lithium has been reported to cause subsmntial alterations in phosphomonoesters in animal studies, presumably due to effects on phosphatidyhdml, phosphatidylethanolamine, and phosphatidylcholine (4-6).
Depression Rating Scak (10) on the day of the MRS study. The avaage duration of illncn was 17.5 years (Sb9.4).
All patients had agrred to discontinue any medications 1 week before the eXanliMtiOn and wcre carchdly monitored for reemergence of symptoms. None of the selected patients had any history of rapid decompensation after discontinuation of medication. A 1-week wdication-free period was chosen besame it was Mt that this time period would not pose a subsranrial risk of relapse for this group of patients One patient had never caken medication, fivepatients had been taking lithium only, two patients had been taking W u m and loratepam, and four patients had been taking carbamaaepim only.
None of the bipolar patients had a history of head injury, organic mental disorder, neurological disorder, schizophrenia or orher psychoric disorder, or anxiety disorder. None of the patients had had clinically signifimnt alcohol or substance abuse in the 12 months bcfore the study. None of the comparidon subjects had my history of major medical illness, head injury, neurological disorder, psychiatric disorder, or clinically significant alcohol or substance abuse. There were no signhnt group differences between patients and comparison subin age or education.
All MRS studies were performed on a Philips Gyroscan SlS MRYMRS system operating at 2 T. A standard irnaging saddletype proton head coil was used for magnetic msonarm imaging (MRI). MRS data volumes were reconstructed, and the effective voxel size was 25 an3. A reference image of the total 31P signal was gencrated, and the higher rrsolution of the spatiaUy registered magnetic resonance images was used to select two vox& in comparabk locations for each s u b j j in the right and left frontal lobes (figure l). 3*P spectra from these voxels were fit by using NMR-1 data processing s o h a m (New Mahods Research, Inc., Syracuse, N.Y.). The percentages of total phosphorow signal for phoQphomonoesun, inorganic phosphate, phosphodiesters, phosphocreatine, and &ATP were calculated. The &ATP resonance was selected to best represent the ATP concentration in tissue because, unlike the g-ATP and a-ATF' resonances (which were also fit by NMR-1 software and included in the n o m a l i t i o n of the ratios), it k free from signal contribution from other phosphate-containing metabolites, such as ADP and niootinamide adenine dmrackotide phosphates. The spectra were coded for blind processing by a single operator to eliminate interoperator variance.
Repeated measures analysis of VariVKe (ANOVA) was used for phosphorous signal for each metabolite, group was the becwear-sub jects factor, and side (kft m u s right) was the within-subjects repeated measures factor. The ANOVAs were performed in an exploratory fashion without correction for multiple comparisons. The signifioula kvel was set at p4.05. data analysis. The dependent variable was t h c p e r c e n q of the t o d to-left ratio of frontal phosphocreatine was higher in the bipolar patients. No such asymmetry of phosphocreatine was noted in the comparison group. There were no group differences or lateralid asymmetries for inorganic phosphate, BATP, pH, or total phosphorous signal.
RESULTS

No
DISCUSSION
The primary finding of this preliminary study was significantly lower phosphomonoester values and higher phosphodiester values in both the right and left frontal lobes of unrnedicated, euthymic bipolar patients than in healthy comparison subjects. The phosphornonoester findings are consistent with prior results from investigations of lithium-treated euthymic bipolar patients; however, we also noted high phosphodiester values in our patient group, which to our knowledge have not been reported before. The results are also similar to those from in vivo 31P MRS studies in schizophrenia, which have shown low phosphomonoester values and high phosphodiester values in the frontal lobes (12) (13) (14) . This suggests that abnormal frontal lobe phospholipid metabolism may play a role in the pathophysiology of both bipolar disorder and schizophrenia.
It appears less likely that the observed abnormalities in phosphomonoesters are related to lithium effects on phospholipids because the seven lithium-treated patients had been medication free for l week and four other patients had been maintained on carbamazepine and not lithium. In addition, low phosphomonoester values were reported for a group of 10 euthymic bipolar patients, seven of whom had not been treated with lithium (2). It has therefore been suggested that an abnormal frontal lobe phosphomonoester value in the euthyrnic state is a traitdependent abnormality, possibly related to membrane abnormalities in bipolar dlsorder (2, 3). Nevertheless, chroNc administration of lithium has been reported to 1) decrease both in vitro levels of phospha tidylinositol and phosphatidylethanolamine and increase phosphatidylcholine in rats ( 5 ) and 2) cause a large initialiincrease and subsequent decline to normal levels of tin vivo phosphomonoester measurements in cats (4). To our knowledge, there is no clear evidence on the time course over which lithium effects on phospholipids resolve. Thus, it is conceivable that any underlying phospholipid changes in humans due to lithium might have persisted beyond the 7-day medication-free period in this study.
A secondary finding of this study, which to our knowledge has not been reported previously, is an asymmetry of phosphocreatine in the bipolar patients, who demonstrated higher phosphocreatine values in the right than left frontal lobe. However, because our study employed metabolite ratios (percentage of total phosphorous signal for each metabolite), it is not possible to definitively conclude whether the right or left frontal lobe has the abnormal metabolite concentraAm J Psychiatry 152:6, june 1995 tion. It is also unclear whether the observed asymmetry is in part due to a difference in atrophy between the right and left frontal lobes. Although there were no qualitative differences in atrophy between the bipolw patients and comparison group or between the right and left sides, more quantitative analyses are required. Moreover, we did not observe a lateralized difference in all phosphorous metabolites or the total phosphorous signal, which would most likely follow from a significant difference in size or atrophy between the right and left frontal lobes. Future studies with larger subject groups, absolute quantitation of phosphorous metabolites, and tissue segmentation techniques (to assess the relative contributions of gray matter, white matter, and CSF in selected voxels) will be able to determine whether the phosphocreatine asymmetry reflects a true concentration difference.
With regard to the limitations of the present study, our study group was small and it is not clear whether the 7-day medication-free period was sufficient to .cornpletely exclude lithium-induced effects on phosphomonoesters. Future studies will be able to address this question by examining whether the observed changes are present in patients who either have been maintained without lithium for a longer period of time or are taking mood stabilizers that are not known to affect phosphomonoesters, such as carbamazepine and valproic acid. Second, abnormalities in the T1 or Tz of phosphorous metabolites in the frontal lobes of the bipolar patients might also have contributed to the observed group differences. In other words, the differences observed here may have reflected differences in metabolite variability (as a consequence of relaxation time differences) rather than metabolite concentration differences. Third, a recognized limitation of in vivo spectroscopy is the low sensitivity of 3*P M R S and the low concentrations of 31P metabolites, which limit the spatial resolution of 31P -MRS. Fourth, the voxels selected for each subject contain varying percentages of gray matter, white matter, and CSF, which also need to be quantitatively determined. In future studies, MRI segmentation software will be interfaced with 31P MRS to determine the exact percentages of gray matter, white matter, and CSF in selected voxels.
